Analysts lowered the average one-year price target for OptimizerRx to $11.73 per share. This revision represents a 20.69% decrease from the previous estimate of $14.79. Current analyst targets for the stock range from a low of $7.07 to a high of $18.90.
A June 9, 2026, analysis highlighted a significant credibility problem facing the company. The report cited accounting concerns, auditor changes, and previous guidance cuts as primary drivers of investor distrust. While OptimizerRx operates in a valuable healthcare marketing segment, the stock remains a bet on management's ability to restore execution and reliability.